scholarly journals Perceived Psychotherapist's Empathy and Therapy Motivation as Determinants of Long-Term Therapy Success—Results of a Cohort Study of Short Term Psychodynamic Inpatient Psychotherapy

2018 ◽  
Vol 9 ◽  
Author(s):  
Frank Vitinius ◽  
Stephanie Tieden ◽  
Martin Hellmich ◽  
Holger Pfaff ◽  
Christian Albus ◽  
...  
Keyword(s):  
Cohort Study ◽  
Term Therapy ◽  
Inpatient Psychotherapy ◽  
Short Term ◽  
Long Term Therapy ◽  
Therapy Success

Clinical and Pharmacokinetic Evaluation of Long-Term Therapy With Didanosine in Children with HIV Infection

PEDIATRICS ◽  
1994 ◽  
Vol 94 (5) ◽  
pp. 724-731 ◽  
Author(s):  
Brigitta U. Mueller ◽  
Karina M. Butler ◽  
Vicki L. Stocker ◽  
Frank M. Balis ◽  
Philip A. Pizzo ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Area Under The Curve ◽  
Chronic Administration ◽  
Cd4 Count ◽  
Term Therapy ◽  
Short Term ◽  
Apparent Relationship ◽  
Term Administration ◽  
Long Term Therapy

Background. Didanosine has demonstrated promising antiviral activity and a tolerable toxicity profile in short term studies. We describe a cohort of HIV-infected children who were treated for a prolonged period of time with didanosine. Methods. Children (6 months to 18 years of age) with symptomatic HIV infection or an absolute CD4 count < 0.5 x 109 cells/L, received oral didanosine at doses between 20 mg/m2 to 180 mg/m2 every 8 hours. Clinical, immunological, and virological parameters were assessed at least every 2 months. The pharmacokinetics of didanosine were evaluated in 85 patients. Results. Previously untreated children (n = 51) and children who had received prior antiretroviral therapy (n = 52) were enrolled in the study (median time on study 22.6 months; range 2 to 48). The long-term administration of didanosine was well tolerated and no new toxicities were observed. The absolute CD4 count increased by ≥ .05 x 109 cells/L in 28 of 87 (32%) of patients after 6 months of therapy. Responses were also sustained in 41% of these children after 3 years of therapy. Children entering the study with a CD4 count >0.1 x 109 cells/L (n = 51) had a marked survival advantage (P = .00002) with an estimated survival probability after 3 years of 80% compared to 39% for children with lower CD4 counts. Although the area under the curve of didanosine increased proportionally with the dose, there was considerable interpatient variability at each dose level. There was no apparent relationship between surrogate markers of clinical outcome and plasma drug concentration. Conclusions. Didanosine was well tolerated with chronic administration, and toxicities were uncommon and usually reversible. In 41% of patients, the CD4 count increased and was maintained at the higher level even after years of treatment.

scholarly journals Ambulatory Intravenous Antibiotic Therapy in Quebec: The Hôpital Charles LeMoyne Experience in 1996

2000 ◽  
Vol 11 (suppl a) ◽  
pp. 6A-10A
Author(s):  
Laurent Delorme ◽  
Charles Frenette ◽  
Isabelle Le Corre ◽  
Julie Duchesne ◽  
Carole Delorme ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Term Therapy ◽  
Outpatient Therapy ◽  
Short Term ◽  
Intravenous Antibiotic ◽  
Therapy Program ◽  
Intravenous Antibiotic Therapy ◽  
Short Term Therapy ◽  
Long Term Therapy

From January 1, 1996 to December 31, 1996, 343 patients received outpatient intravenous antibiotic therapy at Charles LeMoyne Hospital, a 436-bed, acute care hospital in Greenfield Park, south of Montréal, Québec. The infectious diseases department saved 2660 bed-days using outpatient therapy. The mean duration of outpatient therapy was 7.76 days; 81.6% of patients were admitted to the program directly from the emergency room, or outpatient hospital clinics or private offices in the community. Hospitalized patients constituted only 18.4% of admissions to the outpatient intravenous antibiotic therapy program. Forty per cent of the surgical/medical staff participated in the program and they were able to generate a significant impact by diverting patients to outpatient therapy. Two types of patients can benefit from an outpatient intravenous antibiotic therapy program. One group of patients needs empirical short term therapy and can be switched to oral sequential therapy after two to five days of outpatient intravenous antibiotic therapy. A second group of patients needs specific long term therapy for the full duration of the antibiotic therapy. Empirical short term therapy can be managed by emergency department or hospital-based primary physicians, or medical/surgical specialists. Specific long term therapy can be managed by microbiology/infectious disease specialists or medical/surgical specialists. Hospitals that want to relieve pressure on emergency rooms and hospital bed demands should create facilities for both types of patients. Cefazolin and gentamicine/tobramycine were the most commonly used antibiotics in empirical short term therapy and in terms of number of patients treated. Ceftriaxone and vancomycin were most commonly used for long term therapy. The Drug acquisition antibiotic cost was $73,117 but constituted only 20% of the total outpatient intravenous antibiotic therapy cost. The per diem ambulatory cost was $140/patient/day.

Selective Streptokinase Fibrinolysis in Femoro-Iliac Arterial Obstruction

1986 ◽  
Vol 27 (3) ◽  
pp. 279-283 ◽  
Author(s):  
K. Sørensen ◽  
V. Hegedüs
Keyword(s):  
Low Dose ◽  
Transluminal Angioplasty ◽  
Term Therapy ◽  
High Dose ◽  
Short Term ◽  
Short Term Therapy ◽  
One Year ◽  
High Level ◽  
Long Term Therapy

Percutaneous transluminal angioplasty of iliac and femoral arteries was in 17 patients combined with selective intra-arterial streptokinase treatment. The patients were divided into two groups, one given low dose long-term therapy and the other high dose short-term therapy. The experiences obtained during an observation period of over one year revealed greater benefit from high dose short-term therapy. It seems that the major cause of complications must be attributed to the development of a high level of streptokinase antibodies during low dose long-term therapy. References

scholarly journals Short-term Fluconazole Therapy for the Treatment of Candiduria in ICU and ICU Step-down Patients

2015 ◽  
Vol 6 ◽  
pp. CMTIM.S20140
Author(s):  
G. Christopher Wood ◽  
Katarzyna Adamczyk ◽  
Bradley A. Boucher ◽  
Martin A. Croce ◽  
David A. Kuhl ◽  
...  
Keyword(s):  
Critically Ill ◽  
Recurrence Rate ◽  
Critically Ill Patients ◽  
Fungal Resistance ◽  
Term Therapy ◽  
Short Term ◽  
Short Term Treatment ◽  
Step Down ◽  
Long Term Therapy

Objective Candiduria is very common in critically ill patients. It is often benign; however, it can develop into a serious systemic infection and treatment is suggested in symptomatic critically ill patients. The optimal duration of therapy is unclear. Long-term therapy (14 days) is recommended by the current guidelines, but previous data suggest that shorter-duration therapy may be effective. Minimizing the use of antifungal agents is desirable to avoid fungal resistance and adverse events. The purpose of this study was to determine the efficacy of short-term treatment of candiduria. Methods This was an observational study in medical, surgical, and trauma intensive care unit (ICU) and ICU step-down patients. A pathway utilizing a 3-day course of fluconazole for candiduria was implemented. The candiduria recurrence rate was compared in patients treated before (control groups with short-term, ie, ≤3 days, or long–term, ie, ≥7 days, therapy) and after the implementation of the pathway (study group: ≤3 days). Results Thirty-seven study patients were compared to 59 control patients. There were statistically no differences in the recurrence rate for candiduria among study patients, control patients with long-term therapy, and control patients with short-term therapy (32% vs 55% vs 38%, respectively; P > 0.05). Conclusion Three days of fluconazole treatment for candiduria appeared to be as effective as long-term therapy in this population.

Sign in / Sign up

Export Citation Format

Share Document